Table 2 Patient and tumor characteristics in relation to coexistence of AD or HS
From: Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer
AD | HS | Non-hypersensitive | All | ||
|---|---|---|---|---|---|
Number of cases | 125 | 72 | 1508 | 1705 | |
Age at diagnosis of BC | Median (range) | 60.6 (31.5-80.4) | 53.3 (25.4-82.5) | 56.1 (23.6-89.5) | 56.3 (23.6-89.5) |
BMI | Median | 24.6 | 24.1 | 24.2 | 24.2 |
Age at menarche | Median | 13.0 | 13.0 | 13.5 | 13.5 |
Age at menopause | Median | 50.0 | 50.0 | 50.0 | 50.0 |
Deceased | Yes | 57 (46%) | 30 (42%) | 826 (55%) | 913 (54%) |
T-stage | In situ | 4 (3%) | 5 (7%) | 71 (5%) | 80 (5%) |
1 | 68 (54%) | 36 (50%) | 744 (49%) | 848 (50%) | |
2 | 40 (32%) | 23 (32%) | 539 (36%) | 602 (35%) | |
3 | 9 (7%) | 8 (11%) | 104 (7%) | 121 (7%) | |
4 | 0 (0%) | 0 (0%) | 7 (1%) | 7 (0.4%) | |
Unknown | 4 (3%) | 0 (0%) | 43 (3%) | 47 (3%) | |
N-stage | 0 | 54 (43%) | 39 (54%) | 631 (42%) | 724 (43%) |
1 | 44 (35%) | 20 (28%) | 514 (34%) | 578 (34%) | |
2 | 17 (14%) | 8 (11%) | 204 (14%) | 229 (13%) | |
3 | 5 (4%) | 4 (6%) | 91 (6%) | 100 (6%) | |
Unknown | 5 (4%) | 1 (1%) | 68 (5%) | 74 (4%) | |
M-stage | 0 | 117 (94%) | 71 (99%) | 1349 (90%) | 1537 (90%) |
1 | 1 (1%) | 0 (0%) | 24 (2%) | 25 (2%) | |
Unknown | 7 (6%) | 1 (1%) | 135 (9%) | 143 (8%) | |
ER Status | Negative | 20 (16%) | 17 (24%) | 321 (21%) | 358 (21%) |
Positive | 70 (56%) | 33 (46%) | 664 (44%) | 767 (45%) | |
Unknown | 35 (28%) | 22 (31%) | 523 (35%) | 580 (34%) | |
Postmenopausal | No | 32 (26%) | 31 (43%) | 490 (33%) | 553 (32%) |
Yes | 86 (69%) | 39 (54%) | 936 (62%) | 1061 (62%) | |
Unknown | 7 (6%) | 2 (3%) | 82 (5%) | 91 (5%) | |
Screening | No | 78 (62%) | 31 (43%) | 934 (62%) | 1043 (61%) |
Yes | 29 (23%) | 18 (25%) | 274 (18%) | 321 (19%) | |
Unknown | 18 (14%) | 23 (32%) | 300 (20%) | 341 (20%) | |
OCP ever-use | Yes | 50 (40%) | 42 (58%) | 625 (41%) | 717 (42%) |
HRT ever-use | Yes | 31 (25%) | 12 (17%) | 277 (18%) | 320 (19%) |
Parity | 0 | 28 (22%) | 15 (21%) | 250 (17%) | 293 (17%) |
1 | 20 (16%) | 15 (21%) | 284 (19%) | 319 (19%) | |
2 | 56 (45%) | 23 (32%) | 579 (38%) | 658 (39%) | |
3 | 18 (14%) | 10 (14%) | 280 (19%) | 308 (18%) | |
4 + | 3 (2%) | 9 (13%) | 115 (8%) | 127 (7%) | |